

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BALVERSA safely and effectively. See full prescribing information for BALVERSA.

BALVERSA® (erdafitinib) tablets, for oral use
Initial U.S. Approval: 2019

RECENT MAJOR CHANGES

Indications and Usage (1)	01/2024
Dosage and Administration (2.2), (2.3)	01/2024
Warnings and Precautions (5.1), (5.2)	01/2024

INDICATIONS AND USAGE

BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible *FGFR3* genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.

Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. (1, 2.1)

Limitations of Use

BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (1, 14.1)

DOSAGE AND ADMINISTRATION

- Confirm the presence of *FGFR3* genetic alterations in tumor specimens prior to initiation of treatment with BALVERSA. (2.1)
- Recommended initial dosage: 8 mg orally once daily with a dose increase to 9 mg daily if criteria are met. (2.2)
- Swallow whole with or without food. (2.2)

DOSAGE FORMS AND STRENGTHS

Tablets: 3 mg, 4 mg, and 5 mg. (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

- Ocular disorders: BALVERSA can cause central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED). Perform monthly ophthalmological examinations during the first four months of treatment, every 3 months afterwards, and at any time for visual symptoms. Withhold BALVERSA when CSR/RPED occurs and

permanently discontinue if it does not resolve within 4 weeks or if Grade 4 in severity. (2.3, 5.1)

- Hyperphosphatemia: Increases in phosphate levels are a pharmacodynamic effect of BALVERSA. Monitor for hyperphosphatemia and manage with dose modifications when required. (2.3, 5.2)
- Embryo-fetal toxicity: Can cause fetal harm. Advise patients of the potential risk to the fetus and to use effective contraception (5.3, 8.1, 8.3)

ADVERSE REACTIONS

The most common (>20%) adverse reactions, including laboratory abnormalities, were increased phosphate, nail disorders, stomatitis, diarrhea, increased creatinine, increased alkaline phosphatase, increased alanine aminotransferase, decreased hemoglobin, decreased sodium, increased aspartate aminotransferase, fatigue, dry mouth, dry skin, decreased phosphate, decreased appetite, dysgeusia, constipation, increased calcium, dry eye, palmar-plantar erythrodysesthesia syndrome, increased potassium, alopecia, and central serous retinopathy. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Janssen Products, LP, at 1-800-526-7736 (1-800-JANSSEN and www.BALVERSA.com) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Moderate CYP2C9 or strong CYP3A4 inhibitors: Consider alternative agents or monitor closely for adverse reactions. (7.1)
- Strong CYP3A4 inducers: Avoid concomitant use with BALVERSA. (7.1)
- Moderate CYP3A4 inducers: Administer BALVERSA at a dose of 9 mg. (7.1)
- Serum phosphate level-altering agents: Avoid concomitant use with agents that can alter serum phosphate levels before the initial dose modification period. (2.3, 7.1)
- P-gp substrates: Separate BALVERSA administration by at least 6 hours before or after administration of P-gp substrates with narrow therapeutic indices. (7.2)

USE IN SPECIFIC POPULATIONS

- Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 10/2024

FULL PRESCRIBING INFORMATION: CONTENTS*

1	INDICATIONS AND USAGE
2	DOSAGE AND ADMINISTRATION
2.1	Patient Selection
2.2	Recommended Dosage and Schedule
2.3	Dose Modifications for Adverse Reactions
3	DOSAGE FORMS AND STRENGTHS
4	CONTRAINDICATIONS
5	WARNINGS AND PRECAUTIONS
5.1	Ocular Disorders
5.2	Hyperphosphatemia and Soft Tissue Mineralization
5.3	Embryo-Fetal Toxicity
6	ADVERSE REACTIONS
6.1	Clinical Trials Experience
7	DRUG INTERACTIONS
7.1	Effect of Other Drugs on BALVERSA
7.2	Effect of BALVERSA on Other Drugs
8	USE IN SPECIFIC POPULATIONS
8.1	Pregnancy
8.2	Lactation
8.3	Females and Males of Reproductive Potential

8.4	Pediatric Use
8.5	Geriatric Use
8.6	CYP2C9 Poor Metabolizers
11	DESCRIPTION
12	CLINICAL PHARMACOLOGY
12.1	Mechanism of Action
12.2	Pharmacodynamics
12.3	Pharmacokinetics
12.5	Pharmacogenomics
13	NONCLINICAL TOXICOLOGY
13.1	Carcinogenesis, Mutagenesis, and Impairment of Fertility
14	CLINICAL STUDIES
14.1	Urothelial Carcinoma with Susceptible <i>FGFR3</i> Genetic Alterations
16	HOW SUPPLIED/STORAGE AND HANDLING
17	PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible *FGFR3* genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.

Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see *Dosage and Administration (2.1) and Clinical Studies (14.1)*].

Limitations of Use

BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy [see *Clinical Studies (14.1)*].

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection

Select patients for the treatment of locally advanced or metastatic urothelial carcinoma with BALVERSA based on the presence of susceptible *FGFR3* genetic alterations in tumor specimens as detected by an FDA-approved companion diagnostic [see *Clinical Studies (14.1)*].

Information on FDA-approved tests for the detection of *FGFR3* genetic alterations in urothelial cancer is available at: <http://www.fda.gov/CompanionDiagnostics>.

2.2 Recommended Dosage and Schedule

The recommended starting dose of BALVERSA is 8 mg (two 4 mg tablets) orally once daily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on tolerability, including hyperphosphatemia, at 14 to 21 days [see *Dosage and Administration (2.3)*].

Swallow tablets whole with or without food. If vomiting occurs any time after taking BALVERSA, the next dose should be taken the next day. Treatment should continue until disease progression or unacceptable toxicity occurs.

If a dose of BALVERSA is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for BALVERSA the next day. Extra tablets should not be taken to make up for the missed dose.

Dose Increase based on Serum Phosphate Levels

Assess serum phosphate levels 14 to 21 days after initiating treatment. Increase the dose of BALVERSA to 9 mg once daily if serum phosphate level is < 9.0 mg/dL and there are no ocular disorders or Grade 2 or greater adverse reactions. If the phosphate level is 9.0 mg/dL or higher follow the relevant dose modifications in Table 2. Monitor phosphate levels monthly for hyperphosphatemia [see *Pharmacodynamics (12.2)*].

2.3 Dose Modifications for Adverse Reactions

The recommended dose modifications for adverse reactions are listed in Table 1.

Table 1: BALVERSA Dose Reduction Schedule

Dose	1 st dose reduction	2 nd dose reduction	3 rd dose reduction	4 th dose reduction	5 th dose reduction
9 mg → (three 3 mg tablets)	8 mg (two 4 mg tablets)	6 mg (two 3 mg tablets)	5 mg (one 5 mg tablet)	4 mg (one 4 mg tablet)	Stop
8 mg → (two 4 mg tablets)	6 mg (two 3 mg tablets)	5 mg (one 5 mg tablet)	4 mg (one 4 mg tablet)	Stop	

Table 2 summarizes recommendations for dose interruption, reduction, or discontinuation of BALVERSA in the management of specific adverse reactions.

Table 2: Dose Modifications for Adverse Reactions

Adverse Reaction	BALVERSA Dose Modification
Hyperphosphatemia	
In all patients, restrict phosphate intake to 600-800 mg daily.	
<6.99 mg/dL	Continue BALVERSA at current dose.
7-8.99 mg/dL	<ul style="list-style-type: none"> Continue BALVERSA at current dose. Start phosphate binder with food until phosphate level is <7 mg/dL. Reduce the dose if serum phosphate remains ≥ 7 mg/dL for a period of 2 months or if clinically necessary.
9-10 mg/dL	<ul style="list-style-type: none"> Withhold BALVERSA with weekly reassessments until level returns to <7 mg/dL. Then restart BALVERSA at the same dose level. Start phosphate binder with food until serum phosphate level returns to <7 mg/dL. Reduce the dose if serum phosphate remains ≥ 9 mg/dL for a period of 1 month or if clinically necessary.
>10 mg/dL	<ul style="list-style-type: none"> Withhold BALVERSA with weekly reassessments until level returns to <7 mg/dL. Then may restart BALVERSA at the first reduced dose level. If hyperphosphatemia (≥ 10 mg/dL) for >2 weeks, discontinue BALVERSA permanently. Medical management of symptoms as clinically relevant.
Serum phosphate with life-threatening consequences; urgent intervention indicated (e.g., dialysis)	<ul style="list-style-type: none"> Discontinue BALVERSA permanently.
Central Serous Retinopathy (CSR)	
Any	<p>Withhold BALVERSA and perform an ophthalmic evaluation within 2 weeks:</p> <ul style="list-style-type: none"> If improving within 14 days, restart BALVERSA at the current dose. If not improving within 14 days, withhold BALVERSA until improving; once improving, may resume at the next lower dose level. <p>Upon restarting BALVERSA, monitor for recurrence every 1 to 2 weeks for a month. If recurs or has not improved after 4 weeks of withholding BALVERSA, consider permanent discontinuation.</p>
Other Adverse Reactions^a	

Grade 3	Withhold BALVERSA until resolves to Grade 1 or baseline, then may resume dose level lower.
Grade 4	Permanently discontinue.

^a Dose adjustment graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEv5.0).

3 DOSAGE FORMS AND STRENGTHS

Tablets:

- 3 mg: Yellow, round biconvex, film-coated, debossed with “3” on one side; and “EF” on the other side.
- 4 mg: Orange, round biconvex, film-coated, debossed with “4” on one side; and “EF” on the other side.
- 5 mg: Brown, round biconvex, film-coated, debossed with “5” on one side; and “EF” on the other side.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Ocular Disorders

BALVERSA can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect.

In the pooled safety population [see *Adverse Reactions (6)*], CSR/RPED occurred in 22% of patients treated with BALVERSA, with a median time to first onset of 46 days. In 104 patients with CSR, 40% required dose interruptions and 56% required dose reductions; 2.9% of BALVERSA-treated patients required permanent discontinuation for CSR. Of the 24 patients who restarted BALVERSA after dose interruption with or without dose reduction, 67% had recurrence and/or worsening of CSR after restarting. CSR was ongoing in 41% of the 104 patients at the time of last evaluation.

Dry eye symptoms occurred in 26% of BALVERSA-treated patients. All patients should receive dry eye prophylaxis with ocular demulcents as needed.

Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms. Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography.

Withhold or permanently discontinue BALVERSA based on severity and/or ophthalmology exam findings [see *Dosage and Administration (2.3)*].

5.2 Hyperphosphatemia and Soft Tissue Mineralization

BALVERSA can cause hyperphosphatemia leading to soft tissue mineralization, cutaneous calcinosis, non-uremic calciphylaxis and vascular calcification. Increases in phosphate levels are a pharmacodynamic effect of BALVERSA [see *Pharmacodynamics (12.2)*].

In the pooled safety population [see *Adverse Reactions (6)*], increased phosphate occurred in 73% of BALVERSA-treated patients. The median onset time of increased phosphate was 16 days (range: 8-421) after initiating BALVERSA. Twenty-four percent of patients received phosphate binders during treatment with BALVERSA. Vascular calcification was observed in 0.2% of patients treated with BALVERSA.

Monitor for hyperphosphatemia throughout treatment. Restrict dietary phosphate intake (600-800 mg daily) and avoid concomitant use of agents that may increase serum phosphate levels.

If serum phosphate is above 7.0 mg/dL, consider adding an oral phosphate binder until serum phosphate level returns to <7.0 mg/dL. Withhold, dose reduce, or permanently discontinue BALVERSA based on duration and severity of hyperphosphatemia according to Table 2 [see *Dosage and Administration (2.3)*].

5.3 Embryo-Fetal Toxicity

Based on the mechanism of action and findings in animal reproduction studies, BALVERSA can cause fetal harm when administered to a pregnant woman. In an embryo-fetal toxicity study, oral administration of erdafitinib to pregnant rats during the period of organogenesis caused malformations and embryo-fetal death at maternal exposures that were less than the human exposures at the maximum human recommended dose based on area under the curve (AUC). Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment with BALVERSA and for one month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with BALVERSA and for one month after the last dose [see *Use in Specific Populations (8.1, 8.3)* and *Clinical Pharmacology (12.1)*].

6 ADVERSE REACTIONS

The following serious adverse reactions are also described elsewhere in the labeling:

- Ocular Disorders [see *Warnings and Precautions (5.1)*].
- Hyperphosphatemia [see *Warnings and Precautions (5.2)*].

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to BALVERSA as a single agent at the recommended dose (8 to 9 mg orally daily) in 479 patients with advanced urothelial cancer and *FGFR* alterations in 42756493BLC3001 (NCT03390504), 42756493BLC2001 (NCT02365597), 42756493BLC2002 (NCT 03473743), and 42756493EDI1001 (NCT01703481). Among 479 patients who received BALVERSA, the median duration of treatment was 4.8 months (range: 0.1 to 43 months). In this pooled safety population, the most common (>20%) adverse

reactions, including laboratory abnormalities, were increased phosphate, nail disorders, stomatitis, diarrhea, increased creatinine, increased alkaline phosphatase, increased alanine aminotransferase, decreased hemoglobin, decreased sodium, increased aspartate aminotransferase, fatigue, dry mouth, dry skin, decreased phosphate, decreased appetite, dysgeusia, constipation, increased calcium, dry eye, palmar-plantar erythrodysesthesia syndrome, increased potassium, alopecia, and central serous retinopathy.

BLC3001

The safety of BALVERSA was evaluated in Cohort 1 of the BLC3001 study that included patients with locally advanced unresectable or metastatic urothelial carcinoma which had susceptible *FGFR3* genetic alterations and were previously treated with a PD-1 or PD-L1 inhibitor [see *Clinical Studies (14.1)*]. Patients received either BALVERSA (8 mg orally once daily with individualized up-titration to 9 mg) (n=135) or chemotherapy (docetaxel 75 mg/m² once every 3 weeks or vinflunine 320 mg/m² once every 3 weeks) (n=112). Among patients who received BALVERSA, median duration of treatment was 4.8 months (range: 0.2 to 38 months).

Serious adverse reactions occurred in 41% of patients who received BALVERSA. Serious reactions in >2% of patients included urinary tract infection (4.4%), hematuria (3.7%), hyponatremia (2.2%), and acute kidney injury (2.2%). Fatal adverse reactions occurred in 4.4% of patients who received BALVERSA, including sudden death (1.5%), pneumonia (1.5%), renal failure (0.7%), and cardiorespiratory arrest (0.7%).

Permanent discontinuation of BALVERSA due to an adverse reaction occurred in 14% of patients. Adverse reactions which resulted in permanent discontinuation of BALVERSA in >2% of patients included nail disorders (3%) and eye disorders (2.2%).

Dosage interruptions of BALVERSA due to an adverse reaction occurred in 72% of patients. Adverse reactions which required dosage interruption in >4% of patients included nail disorders (22%), stomatitis (19%), eye disorders (16%), palmar-plantar erythrodysesthesia syndrome (15%), diarrhea (10%), hyperphosphatemia (7%), increased aspartate aminotransferase (6%), and increased alanine aminotransferase (5%).

Dose reductions of BALVERSA due to an adverse reaction occurred in 69% of patients. Adverse reactions which required dose reductions in >4% of patients included nail disorders (27%), stomatitis (19%), eye disorders (17%), palmar-plantar erythrodysesthesia syndrome (12%), diarrhea (7%), dry mouth (4.4%), and hyperphosphatemia (4.4%).

Table 3 presents adverse reactions reported in ≥15% of patients treated with BALVERSA at 8 or 9 mg once daily versus chemotherapy.

Table 3: Adverse Reactions Reported in ≥15% of Patients Who Received BALVERSA Versus Chemotherapy (Study BLC3001)

Adverse Reaction	BALVERSA (N=135)		Chemotherapy (N=112)	
	All Grades (%)	Grade 3-4 (%)	All Grades (%)	Grade 3-4 (%)
Skin and subcutaneous tissue disorders				
Nail disorders ^a	70	12	5	0

Palmar-plantar erythrodysesthesia syndrome	30	10	0.9	0
Dry skin ^a	27	1.5	6	0
Alopecia	25	0.7	24	0
Gastrointestinal disorders				
Diarrhea ^a	63	3	17	2.7
Stomatitis ^a	56	10	18	1.8
Dry Mouth	39	0	3.6	0
Constipation	27	0	28	1.8
Nervous system disorders				
Dysgeusia ^a	30	0.7	7	0
General disorders				
Fatigue ^a	29	1.5	42	7
Metabolism and nutrition disorders				
Decreased appetite	27	3	21	2.7
Eye disorders				
Dry eye ^a	25	0.7	3.6	0
Central serous retinopathy ^a	18	2.2	0	0
Investigations				
Decreased weight	22	2	2.7	0

^a Includes multiple terms

Clinically relevant adverse reactions in <15% of patients who received BALVERSA included nausea (15%), pyrexia (15%), epistaxis (13%), vomiting (10%), and arthralgia (10%).

Table 4 presents laboratory abnormalities reported in ≥15% of patients treated with BALVERSA at 8 or 9 mg once daily versus chemotherapy.

Table 4: Selected Laboratory Abnormalities Reported in ≥15% of Patients Who Received BALVERSA Versus Chemotherapy; Cohort 1 Safety Analysis Set (Study BLC3001)

Laboratory Abnormality	BALVERSA (N=135 ¹)		Chemotherapy (N=112 ²)	
	All Grades ³ (%)	Grade 3-4 ³ (%)	All Grades ³ (%)	Grade 3-4 ³ (%)
Chemistry				
Increased phosphate	76	5	0	0
Increased alkaline phosphatase	54	4.7	29	1
Increased alanine aminotransferase	46	3.8	15	1
Increased aspartate aminotransferase	44	3.1	13	0
Decreased sodium	44	16	25	6
Increased creatinine	43	1.5	17	0
Decreased phosphate	34	8	25	3.6
Increased calcium	27	8	9	0
Increased potassium	24	0	21	0
Hematology				
Decreased hemoglobin	50	12	57	12
Decreased platelet count	17	1.5	18	1
Decreased neutrophil count	16	0.8	40	26

- ¹ The denominator used to calculate the rate varied from 52 to 131 based on the number of patients with a baseline value and at least one post-treatment value.
- ² The denominator used to calculate the rate varied from 11 to 102 based on the number of patients with a baseline value and at least one post-treatment value.
- ³ Severity graded per NCI CTCAE v4.03.

BLC2001

The safety of BALVERSA was evaluated in the BLC2001 study that included 87 patients with locally advanced or metastatic urothelial carcinoma which had susceptible *FGFR3* and other *FGFR* alterations, and which progressed during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy [see *Clinical Studies (14.1)*]. Patients were treated with BALVERSA at 8 mg orally once daily; with a dose increase to 9 mg in patients with phosphate levels <5.5 mg/dL on Day 14 of Cycle 1. Median duration of treatment was 5.3 months (range: 0 to 17 months).

Serious adverse reactions occurred in 41% of patients. The most frequent (>3%) serious adverse reactions were central serous retinopathy (4.6%), urinary tract infection (3.4%), and general physical health deterioration (3.4%).

Fatal adverse reactions occurred in 8% of patients, including acute myocardial infarction (1.1%).

Permanent discontinuation of BALVERSA due to an adverse reaction occurred in 21% of patients. The most frequent ($\geq 2\%$) reasons for permanent discontinuation included central serous retinopathy (4.6%), general physical health deterioration (3.4%), palmar-plantar erythrodysesthesia syndrome (2.3%), acute kidney injury (2.3%), and fatigue (2.3%).

Dosage interruptions of BALVERSA occurred in 68% of patients. The most frequent ($\geq 5\%$) adverse reactions requiring dosage interruption included hyperphosphatemia (24%), stomatitis (17%), nail disorders (16%), central serous retinopathy (9%), palmar-plantar erythro-dysesthesia syndrome (8%), and fatigue (8%).

Dose reductions of BALVERSA occurred in 53% of patients. The most frequent ($\geq 5\%$) adverse reactions for dose reductions included nail disorders (21%), stomatitis (15%), central serous retinopathy (14%), hyperphosphatemia (7%), palmar-plantar erythro-dysesthesia syndrome (7%), fatigue (6%), and blurred vision (6%).

Table 5 presents adverse reactions reported in $\geq 15\%$ of patients treated with BALVERSA at 8 mg or 9 mg once daily.

Table 5: Adverse Reactions Reported in $\geq 15\%$ of Patients (Study BLC2001)

Adverse Reaction	BALVERSA 8 mg daily (N=87)	
	All Grades (%)	Grade 3-4 (%)
Gastrointestinal disorders		
Stomatitis ^a	62	11
Diarrhea ^a	48	4.6
Dry mouth	45	0
Constipation	28	1.1
Nausea	21	1.1

Skin and subcutaneous tissue disorders		
Nail disorders ^a	62	14
Dry skin ^a	37	0
Alopecia	26	0
Palmar-plantar erythrodysesthesia syndrome	26	6
General disorders and admin. site conditions		
Fatigue ^{a, b}	54	8
Decreased weight	16	0
Metabolism and nutrition disorders		
Decreased appetite	38	0.0
Nervous system disorders		
Dysgeusia ^a	38	1.1
Eye disorders		
Dry eye ^a	29	1.1
Central serous retinopathy ^a	28	4.6
Blurred vision	17	0
Infections and Infestations		
Urinary tract infection	17	6

^a Includes multiple terms

^b Includes fatal adverse reactions (n=2)

Clinically relevant adverse reactions in <15% of patients who received BALVERSA included pyrexia (14%), extremity pain (13%), vomiting (13%), and peripheral edema (10%).

Table 6 presents laboratory abnormalities reported in $\geq 15\%$ of patients treated with BALVERSA at 8 mg or 9 mg once daily.

Table 6: Selected Laboratory Abnormalities Reported in $\geq 15\%$ of Patients

Laboratory Abnormality	BALVERSA 8 mg daily (N=87 ¹)	
	All Grades (%)	Grade 3-4 (%)
Chemistry		
Increased phosphate	76	1.2
Increased creatinine	52	4.7
Increased alanine aminotransferase	41	1.2
Increased alkaline phosphatase	41	1.2
Decreased sodium	40	16
Decreased magnesium	31	1.2
Increased aspartate aminotransferase	30	0
Decreased phosphate	24	9
Increased calcium	22	3.5
Hematology		
Decreased hemoglobin	35	3.5

Decreased platelets	19	1.2
Decreased leukocytes	17	0

¹ The denominator used to calculate the rate varied from 83 to 86 based on the number of patients with a baseline value and at least one post-treatment value.

7 DRUG INTERACTIONS

7.1 Effect of Other Drugs on BALVERSA

Table 7 summarizes drug interactions that affect the exposure of BALVERSA or serum phosphate level and their clinical management.

Table 7: Drug Interactions that Affect BALVERSA

Moderate CYP2C9 or Strong CYP3A4 Inhibitors	
Clinical Impact	<ul style="list-style-type: none"> Co-administration of BALVERSA with moderate CYP2C9 or strong CYP3A4 inhibitors increased erdafitinib plasma concentrations [see <i>Clinical Pharmacology (12.3)</i>]. Increased erdafitinib plasma concentrations may lead to increased drug-related toxicity [see <i>Warnings and Precautions (5)</i>].
Clinical Management	<ul style="list-style-type: none"> Consider alternative therapies that are not moderate CYP2C9 or strong CYP3A4 inhibitors during treatment with BALVERSA. If co-administration of a moderate CYP2C9 or strong CYP3A4 inhibitor is unavoidable, monitor closely for adverse reactions and consider dose modifications accordingly [see <i>Dosage and Administration (2.3)</i>]. If the moderate CYP2C9 or strong CYP3A4 inhibitor is discontinued, resume the BALVERSA dose before dose modifications in the absence of drug-related toxicity.
Strong CYP3A4 Inducers	
Clinical Impact	<ul style="list-style-type: none"> Co-administration of BALVERSA with strong CYP3A4 inducers decreased erdafitinib plasma concentrations [see <i>Clinical Pharmacology (12.3)</i>]. Decreased erdafitinib plasma concentrations may lead to decreased activity.
Clinical Management	<ul style="list-style-type: none"> Avoid co-administration of strong CYP3A4 inducers with BALVERSA.
Moderate CYP3A4 Inducers	
Clinical Impact	<ul style="list-style-type: none"> Co-administration of BALVERSA with moderate CYP3A4 inducers may decrease erdafitinib plasma concentrations [see <i>Clinical Pharmacology (12.3)</i>]. Decreased erdafitinib plasma concentrations may lead to decreased activity.
Clinical Management	<ul style="list-style-type: none"> If a moderate CYP3A4 inducer must be co-administered at the start of BALVERSA treatment, administer BALVERSA at a dose of 9 mg daily. When a moderate CYP3A4 inducer is discontinued, continue BALVERSA at the same dose, in the absence of drug-related toxicity.
Serum Phosphate Level-Altering Agents	
Clinical Impact	<ul style="list-style-type: none"> Co-administration of BALVERSA with other serum phosphate level-altering agents may increase or decrease serum phosphate levels [see <i>Pharmacodynamics (12.2)</i>]. Changes in serum phosphate levels due to serum phosphate level-altering agents (other than erdafitinib) may interfere with serum phosphate levels needed for the determination of initial dose increased based on serum phosphate levels [see <i>Dosage and Administration (2.3)</i>].
Clinical Management	<ul style="list-style-type: none"> Avoid co-administration of serum phosphate level-altering agents with BALVERSA before initial dose increase period based on serum phosphate levels (Days 14 to 21) [see <i>Dosage and Administration (2.3)</i>].

7.2 Effect of BALVERSA on Other Drugs

Table 8 summarizes the effect of BALVERSA on other drugs and their clinical management.

Table 8: BALVERSA Drug Interactions that Affect Other Drugs

P-glycoprotein (P-gp) Substrates	
Clinical Impact	<ul style="list-style-type: none">• Co-administration of BALVERSA with P-gp substrates may increase the plasma concentrations of P-gp substrates [see <i>Clinical Pharmacology (12.3)</i>].• Increased plasma concentrations of P-gp substrates may lead to increased toxicity of the P-gp substrates.
Clinical Management	<ul style="list-style-type: none">• If co-administration of BALVERSA with P-gp substrates is unavoidable, separate BALVERSA administration by at least 6 hours before or after administration of P-gp substrates with narrow therapeutic index.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on the mechanism of action and findings in animal reproduction studies, BALVERSA can cause fetal harm when administered to a pregnant woman [see *Clinical Pharmacology (12.1)*]. There are no available data on BALVERSA use in pregnant women to inform a drug-associated risk. Oral administration of erdafitinib to pregnant rats during organogenesis caused malformations and embryo-fetal death at maternal exposures that were less than the human exposures at the maximum recommended human dose based on AUC (see *Data*). Advise pregnant women and females of reproductive potential of the potential risk to the fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

In an embryo-fetal toxicity study, erdafitinib was orally administered to pregnant rats during the period of organogenesis. Doses ≥ 4 mg/kg/day (at total maternal exposures $< 0.1\%$ of total human exposures at the maximum recommended human dose based on AUC) produced embryo-fetal death, major blood vessel malformations and other vascular anomalies, limb malformations (ectrodactyly, absent or misshapen long bones), an increased incidence of skeletal anomalies in multiple bones (vertebrae, sternebrae, ribs), and decreased fetal weight.

8.2 Lactation

Risk Summary

There are no data on the presence of erdafitinib in human milk, or the effects of erdafitinib on the breastfed child, or on milk production. Because of the potential for serious adverse reactions from erdafitinib in a

breastfed child, advise lactating women not to breastfeed during treatment with BALVERSA and for one month following the last dose.

8.3 Females and Males of Reproductive Potential

BALVERSA can cause fetal harm when administered to a pregnant woman [*see Use in Specific Populations (8.1)*].

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating treatment with BALVERSA.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with BALVERSA and for one month after the last dose.

Males

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with BALVERSA and for one month after the last dose.

Infertility

Females

Based on findings from animal studies, BALVERSA may impair fertility in females of reproductive potential [*see Nonclinical Toxicology (13.1)*].

8.4 Pediatric Use

Safety and effectiveness of BALVERSA in pediatric patients have not been established.

In 4 and 13-week repeat-dose toxicology studies in rats and dogs, toxicities in bone and teeth were observed at an exposure less than the human exposure (AUC) at the maximum recommended human dose. Chondroid dysplasia/metaplasia were reported in multiple bones in both species, and tooth abnormalities included abnormal/irregular denting in rats and dogs and discoloration and degeneration of odontoblasts in rats.

8.5 Geriatric Use

Of the 479 patients treated with BALVERSA in clinical studies, 40% of patients were less than 65 years old, 40% of patients were 65 years to 74 years old, and 20% were 75 years old and over.

Patients 65 years of age and older treated with BALVERSA experienced a higher incidence of adverse reactions requiring treatment discontinuation than younger patients. In clinical trials, the incidence of treatment discontinuations of BALVERSA due to adverse reactions was 10% in patients younger than 65 years, 20% in patients ages 65-74 years, and 35% in patients 75 years or older.

No overall difference in efficacy was observed between these patients and younger patients [see *Clinical Studies (14.1)*].


8.6 CYP2C9 Poor Metabolizers

*CYP2C9*3/*3 Genotype:* Erdafitinib plasma concentrations are predicted to be higher in patients with the CYP2C9*3/*3 genotype. Monitor for increased adverse reactions in patients who are known or suspected to have CYP2C9*3/*3 genotype [see *Pharmacogenomics (12.5)*].

11 DESCRIPTION

Erdafitinib, the active ingredient in BALVERSA, is a kinase inhibitor. The chemical name is N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine. Erdafitinib is a yellow powder. It is practically insoluble, or insoluble to freely soluble in organic solvents, and slightly soluble to practically insoluble, or insoluble in aqueous media over a wide range of pH values. The molecular formula is C₂₅H₃₀N₆O₂ and molecular weight is 446.56.

Chemical structure of erdafitinib is as follows:



BALVERSA[®] (erdafitinib) tablets are supplied as 3 mg, 4 mg or 5 mg film-coated tablets for oral administration and contains the following inactive ingredients:

Tablet Core: Croscarmellose sodium, Magnesium stearate (from vegetable source), Mannitol, Meglumine, and Microcrystalline Cellulose.

Film Coating: (Opadry amb II): Glycerol monocaprylocaprate Type I, Polyvinyl alcohol-partially hydrolyzed, Sodium lauryl sulfate, Talc, Titanium dioxide, Iron oxide yellow, Iron oxide red (for the orange and brown tablets only), Ferrosoferric oxide/iron oxide black (for the brown tablets only).

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Erdafitinib is a kinase inhibitor that binds to and inhibits enzymatic activity of FGFR1, FGFR2, FGFR3 and FGFR4 based on *in vitro* data. Erdafitinib inhibited FGFR phosphorylation and signaling and decreased cell viability in cell lines expressing *FGFR* genetic alterations, including point mutations,

amplifications, and fusions. Erdafitinib demonstrated antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer.

12.2 Pharmacodynamics

Cardiac Electrophysiology

Based on evaluation of QTc interval in an open-label, dose escalation and dose expansion study in 187 patients with cancer, erdafitinib had no large effect (i.e., > 20 ms) on the QTc interval.

Serum Phosphate

FGFR inhibition by BALVERSA increases serum phosphate level [*see Dosage and Administration (2.3) and Drug Interactions (7.1)*].

12.3 Pharmacokinetics

Following administration of BALVERSA 8 mg once daily, the mean (coefficient of variation [CV%]) erdafitinib steady-state maximum plasma concentration (C_{max}), area under the curve (AUC_{tau}), and minimum plasma concentration (C_{min}) were 1,399 ng/mL (51%), 29,268 ng·h/mL (60%), and 936 ng/mL (65%), respectively.

Following single and repeat once daily dosing of BALVERSA, erdafitinib exposure (C_{max} and AUC) increased proportionally across the dose range of 0.5 to 12 mg (0.06 to 1.3 times the maximum approved recommended dose). Steady state was achieved after 2 weeks with once daily dosing with a mean accumulation ratio was 4-fold.

Absorption

Median time to achieve peak plasma concentration (t_{max}) was 2.5 hours (range: 2 to 6 hours).

Effect of Food

No clinically meaningful differences in erdafitinib exposure was observed following administration of BALVERSA with a high-fat and high-calorie meal (800 calories to 1,000 calories with approximately 50% of total caloric content of the meal from fat).

Distribution

The mean apparent volume of distribution of erdafitinib was 29 L.

Erdafitinib protein binding was 99.7% in patients, primarily to alpha-1-acid glycoprotein.

Elimination

The mean total apparent clearance (CL/F) of erdafitinib was 0.362 L/h.

The mean effective half-life of erdafitinib was 59 hours.

Metabolism

Erdaftinib is primarily metabolized by CYP2C9 and CYP3A4. The contribution of CYP2C9 and CYP3A4 in the total clearance of erdaftinib is estimated to be 39% and 20%, respectively. Unchanged erdaftinib was the major drug-related moiety in plasma, there were no circulating metabolites.

Excretion

Following a single oral dose of radiolabeled erdaftinib, approximately 69% of the dose was recovered in feces (19% as unchanged) and 19% in urine (13% as unchanged).

Specific Populations

No clinically meaningful effects on erdaftinib exposure were observed based on age (21-92 years), sex, race (White, Hispanic or Asian), body weight (36-166 kg), mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment, or mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²). Limited data are available in patients with severe (Child-Pugh C) hepatic impairment and in patients with severe renal impairment. The pharmacokinetics of erdaftinib in patients with renal impairment requiring dialysis is unknown.

Drug Interaction Studies

Clinical Studies

Effect of Other Drugs on Erdaftinib

Moderate CYP2C9 Inhibitors

Erdaftinib mean ratios for C_{max} and AUC_{inf} were 121% and 148%, respectively, when BALVERSA was co-administered with fluconazole, a moderate CYP2C9 and CYP3A4 inhibitor, relative to BALVERSA administered alone.

Strong CYP3A4 Inhibitors

Erdaftinib mean ratios for C_{max} and AUC_{inf} were 105% and 134%, respectively, when BALVERSA was co-administered with itraconazole (a strong CYP3A4 inhibitor and P-gp inhibitor) relative to BALVERSA alone.

CYP3A4/2C9 Inducers

Erdaftinib mean ratios for C_{max} and AUC_{inf} were 78% and 45%, respectively, when BALVERSA was co-administered with carbamazepine (a strong CYP3A4 and weak CYP2C9 inducer) relative to BALVERSA alone.

Effect of Erdaftinib on Other Drugs

CYP3A4 Substrates:

No clinically meaningful effect on the exposure of midazolam (a CYP3A4 substrate) was observed following coadministration with BALVERSA.

OCT2 Substrates:

No clinically meaningful effect on the exposure of metformin (an OCT2 substrate) was observed following coadministration with BALVERSA.

In Vitro Studies

CYP Substrates

Erdafitinib is a time dependent inhibitor and inducer of CYP3A4. Erdafitinib is not an inhibitor of other major CYP isozymes at clinically relevant concentrations.

Transporters

Erdafitinib is a substrate and inhibitor of P-gp. P-gp inhibitors are not expected to affect erdafitinib exposure to a clinically relevant extent. Erdafitinib is an inhibitor of OCT2.

Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.

Acid-Lowering Agents

Erdafitinib has adequate solubility across the pH range of 1 to 7.4. Acid-lowering agents (including antacids, H₂-antagonists and proton pump inhibitors) are not expected to affect the bioavailability of erdafitinib.

12.5 Pharmacogenomics

CYP2C9 activity is reduced in individuals with genetic variants, such as the CYP2C9*2 and CYP2C9*3 polymorphisms. Erdafitinib exposure was similar in subjects with CYP2C9*1/*2 and *1/*3 genotypes relative to subjects with CYP2C9*1/*1 genotype (wild type). No data are available in subjects characterized by other genotypes (e.g., *2/*2, *2/*3, *3/*3). Simulation suggested no clinically meaningful differences in erdafitinib exposure in subjects with CYP2C9*2/*2 and *2/*3 genotypes. The exposure of erdafitinib is predicted to be 50% higher in subjects with the CYP2C9*3/*3 genotype, estimated to be present in 0.4% to 3% of the population among various ethnic groups.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility

Carcinogenicity studies have not been conducted with erdafitinib.

Erdafitinib was not mutagenic in a bacterial reverse mutation (Ames) assay and was not clastogenic in an *in vitro* micronucleus or an *in vivo* rat bone marrow micronucleus assay.

Fertility studies in animals have not been conducted with erdafitinib. In the 3-month repeat-dose toxicity study, erdafitinib showed effects on female reproductive organs (necrosis of the ovarian corpora lutea) in rats at an exposure less than the human exposure (AUC) at maximum recommended human dose.

14 CLINICAL STUDIES

14.1 Urothelial Carcinoma with Susceptible *FGFR3* Genetic Alterations

The efficacy of BALVERSA was evaluated in Study BLC3001 (NCT03390504) Cohort 1, a randomized, open-label, multicenter study in which 266 patients with advanced urothelial cancer harboring selected *FGFR3* alterations were randomized 1:1 to receive BALVERSA (8 mg with titration up to 9 mg) versus chemotherapy (docetaxel 75 mg/m² once every 3 weeks or vinflunine 320 mg/m² once every 3 weeks) until unacceptable toxicity or progression. Randomization was stratified by region (North America vs. Europe vs. rest of world), Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1 vs. 2) and visceral or bone metastases (yes vs. no). All patients needed to have had disease progression after 1 or 2 prior treatments, at least 1 of which included a PD-1 or PD-L1 inhibitor. *FGFR3* genetic alterations were identified from tumor tissue in a central laboratory by the QIAGEN *therascreen*[®] *FGFR* RGQ RT-Polymerase Chain Reaction (PCR) kit in 75% of patients while the remainder (25%) were identified by local next generation sequencing (NGS) assays.

The major efficacy outcome measures were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) assessed by investigator using RECIST (Response Evaluation Criteria in Solid Tumors) Version 1.1.

The median age was 67 years (range: 32 to 86 years) and 71% were male; 54% were White, 29% Asian, 0.4% Black, 0.4% multiple races, 16% not reported; 2% were Hispanic/Latino; and baseline ECOG performance status was 0 (43%), 1 (48%), or 2 (9%). Eighty-one percent of patients had *FGFR3* mutations, 17% had fusions, and 2% had both mutations and fusions. Ninety-five percent of patients had pure transitional cell carcinoma (TCC) and 5% had TCC with other histologic variants. The primary tumor location was the upper tract for 33% of subjects and lower tract for 67%; 74% of patients had visceral or bone metastases. Eighty-eight percent of patients received platinum-containing chemotherapy previously. PD-1 or PD-L1 inhibitor therapy was received only in the neoadjuvant or adjuvant setting in 7% of patients.

Statistically significant improvements in OS, PFS, and ORR were demonstrated for BALVERSA compared with chemotherapy.

Table 9 and Figures 1 and 2 summarize the efficacy results for BLC3001 Cohort 1.

Table 9: Efficacy Results for Study BLC3001 Cohort 1


	BALVERSA N=136	Chemotherapy N=130
Overall Survival (OS)		
Number of events (%)	77 (56.6%)	78 (60.0%)
Median ^a , months (95% CI)	12.1 (10.3, 16.4)	7.8 (6.5, 11.1)
Hazard ratio ^b (95% CI)	0.64 (0.47, 0.88)	
p-value ^c	0.0050	
Progression-free survival (PFS)		
Number of events (%)	101 (74.3%)	90 (69.2%)
Median ^a , months (95% CI)	5.6 (4.4, 5.7)	2.7 (1.8, 3.7)
Hazard ratio ^b (95% CI)	0.58 (0.44, 0.78)	
p-value ^c	0.0002	
Objective response rate (ORR)		
ORR (95% CI)	35.3% (27.3, 43.9)	8.5% (4.3, 14.6)
p-value ^d	<0.001	

Complete response, CR (%)	5.1%	0.8%
Partial response, PR (%)	30.1%	7.7%

All p-values reported are 2-sided and compared with 0.019 of the allocated alpha for the interim analysis.

- ^a Based on Kaplan-Meier estimates
 - ^b Based on an unstratified Cox proportional hazard model
 - ^c Based on an unstratified log-rank test
 - ^d p-value is estimated using Cochran-Haenszel (CMH) test with ECOG performance status (0 or 1 vs 2) as a stratification factor.
- ORR = confirmed objective response (CR + PR)
CI = Confidence Interval


Figure 1: Kaplan-Meier Plot of Overall Survival (Study BLC3001 Cohort 1)



Subjects at risk

Erdafitinib	136	117	97	74	46	35	25	17	15	9	5	3	3	2	2	2	1	0
Chemotherapy	130	87	66	43	30	18	13	9	8	3	2	2	1	0	0	0	0	0

Figure 2: Kaplan-Meier Plot of Progression-free Survival (Study BLC3001 Cohort 1)



Subjects at risk

Erdafitinib	136	90	39	24	12	7	3	3	3	2	1	1	0
Chemotherapy	130	43	23	9	4	2	2	1	1	0	0	0	0

Study BLC3001 Cohort 2

Study BLC3001 (NCT03390504) Cohort 2 was a multicenter, open-label, randomized study in 351 patients with locally advanced or metastatic urothelial carcinoma with selected *FGFR3* alterations who received 1 prior line of systemic therapy and no prior PD-1 or PD-L1 inhibitor. Patients were randomized 1:1 to receive BALVERSA (8 mg with titration up to 9 mg) or pembrolizumab 200 mg every 3 weeks. The study did not meet its major efficacy outcome measure for superiority of OS at the pre-specified final analysis. The OS hazard ratio (HR) was 1.18 (95% CI: 0.92, 1.51; $p=0.18$), median 10.9 (95% CI: 9.2, 12.6) months for BALVERSA versus 11.1 (95% CI: 9.7, 13.6) months for pembrolizumab [see *Indications and Usage (1)*].

Study BLC2001

Study BLC2001 (NCT02365597) was a multicenter, open-label, single-arm study to evaluate the efficacy and safety of BALVERSA in patients with locally advanced or metastatic urothelial carcinoma (mUC). *FGFR* mutation status for screening and enrollment of patients was determined by a clinical trial assay (CTA). The efficacy population consists of a cohort of eighty-seven patients who were enrolled in this study with disease that had progressed on or after at least one prior chemotherapy and that had at least 1 of the following genetic alterations: *FGFR3* gene mutations (*R248C*, *S249C*, *G370C*, *Y373C*) or *FGFR*

gene fusions (*FGFR3-TACC3*, *FGFR3-BALAP2L1*, *FGFR2-BICC1*, *FGFR2-CASP7*), as determined by the CTA performed at a central laboratory. Tumor samples from 69 patients were tested retrospectively by the QIAGEN *therascreen*[®] *FGFR* RGQ RT-PCR Kit, which is the FDA-approved test for selection of patients with mUC for BALVERSA.

Patients received a starting dose of BALVERSA at 8 mg once daily with a dose increase to 9 mg once daily in patients whose serum phosphate levels were below the target of 5.5 mg/dL between days 14 and 17; a dose increase occurred in 41% of patients. BALVERSA was administered until disease progression or unacceptable toxicity. The major efficacy outcome measures were ORR and duration of response (DoR), as determined by blinded independent review committee (BIRC) according to RECIST v1.1.

The median age was 67 years (range: 36 to 87 years), 79% were male, and 74% were Caucasian. Most patients (92%) had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Sixty-six percent of patients had visceral metastases. Eighty-four (97%) patients received at least one of cisplatin or carboplatin previously. Fifty-six percent of patients only received prior cisplatin-based regimens, 29% received only prior carboplatin-based regimens, and 10% received both cisplatin and carboplatin-based regimens. Three (3%) patients had disease progression following prior platinum-containing neoadjuvant or adjuvant therapy only. Twenty-four percent of patients had been treated with prior anti PD-L1/PD-1 therapy.

Efficacy results are summarized in Table 10 and Table 11. ORR was 32.2%. Responders included patients who had previously not responded to anti PD-L1/PD-1 therapy.

Table 10: Efficacy Results

Endpoint	BIRC ^a Assessment
	N=87
ORR (95% CI)	32.2% (22.4, 42.0)
Complete response (CR)	2.3%
Partial response (PR)	29.9%
Median DoR in months (95% CI)	5.4 (4.2, 6.9)

^a BIRC: Blinded Independent Review Committee

ORR = CR + PR

CI = Confidence Interval

Table 11: Efficacy Results by *FGFR* Genetic Alteration

	BIRC^a Assessment
<i>FGFR3</i> Point Mutation	N=64
ORR (95% CI)	40.6% (28.6, 52.7)
<i>FGFR3</i> Fusion ^{b, c}	N=18
ORR (95% CI)	11.1% (0, 25.6)
<i>FGFR2</i> Fusion ^c	N=6
ORR	0

^a BIRC: Blinded Independent Review Committee

^b Both responders had *FGFR3*-TACC3_V1 fusion

^c One patient with a *FGFR2*-CASP7/*FGFR3*-TACC3_V3 fusion is reported in both *FGFR2* fusion and *FGFR3* fusion above

ORR = CR + PR

CI = Confidence Interval

16 HOW SUPPLIED/STORAGE AND HANDLING

BALVERSA[®] (erdafitinib) tablets are available in the strengths and packages listed below:

- 3 mg tablets: Yellow, round biconvex, film-coated, debossed with “3” on one side and “EF” on the other side.
 - Bottle of 56-tablets with child resistant closure (NDC 59676-030-56).
 - Bottle of 84-tablets with child resistant closure (NDC 59676-030-84).
- 4 mg tablets: Orange, round biconvex, film-coated, debossed with “4” on one side and “EF” on the other side.
 - Bottle of 28-tablets with child resistant closure (NDC 59676-040-28).
 - Bottle of 56-tablets with child resistant closure (NDC 59676-040-56).
- 5 mg tablets: Brown, round biconvex, film-coated, debossed with “5” on one side and “EF” on the other side.
 - Bottle of 28-tablets with child resistant closure (NDC 59676-050-28).

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [*see USP Controlled Room Temperature*].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

FGFR Genetic Alterations

Advise patients that evidence of a susceptible *FGFR3* mutation or gene fusion within the tumor specimen is necessary to identify patients for whom treatment is indicated [*see Dosage and Administration (2.1)*].

Ocular Disorders

Advise patients to contact their healthcare provider if they experience any visual changes [*see Warnings and Precautions (5.1)*]. In order to prevent or treat dry eyes, advise patients to use artificial tear substitutes, hydrating or lubricating eye gels or ointments frequently, at least every 2 hours during waking hours [*see Dosage and Administration (2.3)*].

Skin, Mucous or Nail Disorders

Advise patients to contact their healthcare provider if they experience progressive or intolerable skin, mucous or nail disorders [*see Adverse Reactions (6.1)*].

Hyperphosphatemia and Soft Tissue Mineralization

Inform patients that BALVERSA may cause hyperphosphatemia and soft tissue mineralization. Advise patients to immediately inform their healthcare provider of painful skin lesions or any symptoms related to acute change in phosphate levels such as muscle cramps, numbness, or tingling around the mouth [*see Warnings and Precautions (5.2)*].

Advise patients that their healthcare provider will assess their serum phosphate level between 14 and 21 days of initiating treatment and will adjust the dose if needed [*see Warnings and Precautions (5.2)*]. Advise patients to restrict phosphate intake to 600-800 mg daily. During this initial phosphate-assessment period, advise patients to avoid concomitant use with agents that can alter serum phosphate levels. Advise patients that, after the initial phosphate assessment period, monthly phosphate level monitoring for hyperphosphatemia should be performed during treatment with BALVERSA [*see Drug Interactions (7.1)*].

Drug Interactions

Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, and herbal products [*see Drug Interactions (7.1, 7.2)*].

Dosing Instructions

Instruct patients to swallow the tablets whole once daily with or without food. If vomiting occurs any time after taking BALVERSA, advise patients to take the next dose the next day [*see Dosage and Administration (2.2)*].

Missed Dose

If a dose is missed, advise patients to take the missed dose as soon as possible. Resume the regular daily dose schedule for BALVERSA the next day. Extra tablets should not be taken to make up for the missed dose [*see Dosage and Administration (2.3)*].

Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females to inform their healthcare providers of a known or suspected pregnancy [*see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)*].

Advise female patients of reproductive potential to use effective contraception during treatment and for one month after the last dose of BALVERSA. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for one month after the last dose of BALVERSA [*see Use in Specific Populations (8.3)*].

Lactation

Advise females not to breastfeed during treatment with BALVERSA and for one month after the last dose [*see Use in Specific Populations (8.2)*].

Infertility

Advise females of reproductive potential that BALVERSA may impair fertility [*see Use in Specific Populations (8.3)*].

Product of Switzerland

Manufactured for:
Janssen Products, LP
Horsham, PA 19044, USA

Under license from Astex Therapeutics Limited.

For patent information: www.janssenpatents.com

©2019 Janssen Pharmaceutical Companies

PATIENT INFORMATION
BALVERSA® (bal-VER-sah)
(erdafitinib) tablets

What is BALVERSA?

BALVERSA is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery:

- which has a certain type of abnormal FGFR gene, **and**
- who have tried at least one other medicine by mouth or injection (systemic therapy) that did not work or is no longer working.

Your healthcare provider will test your cancer for certain types of abnormal FGFR genes and make sure that BALVERSA is right for you.

BALVERSA is not recommended for the treatment of people who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.

It is not known if BALVERSA is safe and effective in children.

Before taking BALVERSA tell your healthcare provider about all of your medical conditions, including if you:

- have vision or eye problems.
- are pregnant or plan to become pregnant. BALVERSA can harm your unborn baby. You should not become pregnant during treatment with BALVERSA.

Females who can become pregnant:

- Your healthcare provider may do a pregnancy test before you start treatment with BALVERSA.
- You should use effective birth control during treatment and for 1 month after the last dose of BALVERSA. Talk to your healthcare provider about birth control methods that may be right for you.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant.

Males with female partners who can become pregnant:

- You should use effective birth control when sexually active during treatment with BALVERSA and for 1 month after the last dose.
- are breastfeeding or plan to breastfeed. Do not breastfeed during treatment and for 1 month after the last dose of BALVERSA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take BALVERSA?

- Take BALVERSA exactly as your healthcare provider tells you.
- Take BALVERSA 1 time each day.
- Swallow BALVERSA tablets whole with or without food.
- Your healthcare provider may change your dose of BALVERSA, temporarily stop or completely stop treatment if you get certain side effects.
- If you miss a dose of BALVERSA, take the missed dose as soon as possible on the same day. Take your regular dose of BALVERSA the next day. Do not take more BALVERSA than prescribed to make up for the missed dose.
- If you vomit after taking BALVERSA, do not take another BALVERSA tablet. Take your regular dose of BALVERSA the next day.

What are the possible side effects of BALVERSA?

BALVERSA may cause serious side effects, including:

- **Eye problems.** Eye problems are common with BALVERSA but can also be serious. Eye problems include dry or inflamed eyes, inflamed cornea (front part of the eye) and disorders of the retina, an internal part of the eye. Tell your healthcare provider right away if you develop blurred vision, loss of vision or other visual changes. You should use artificial tear substitutes, hydrating or lubricating eye gels or ointments at least every 2 hours during waking hours to help prevent dry eyes. During treatment with BALVERSA, your healthcare provider will send you to see an eye specialist.

- **High phosphate levels in the blood (hyperphosphatemia).** Hyperphosphatemia is common with BALVERSA but can also be serious. High levels of phosphate in your blood may lead to build-up of minerals such as calcium in different tissues in your body. Your healthcare provider will check your blood phosphate level between 14 and 21 days after starting treatment with BALVERSA, and then monthly.
 - Your healthcare provider may prescribe changes in your diet or phosphate lowering therapy, or change or stop treatment with BALVERSA if needed.
 - Tell your healthcare provider right away if you develop painful skin lesions, any muscle cramps, or numbness or tingling around your mouth.

The most common side effects of BALVERSA include:

- nails separate from the bed or poor formation of the nail
- mouth sores
- diarrhea
- increased level of creatinine in the blood
- increased level of the enzyme alkaline phosphatase in the blood
- change in liver function
- decreased red blood cells (anemia)
- decreased salt (sodium) levels in the blood
- tiredness
- dry mouth
- dry skin
- decreased phosphate in the blood
- decreased appetite
- change in sense of taste
- constipation
- increased level of calcium in the blood
- dry eye
- redness, swelling, peeling or tenderness, mainly on the hands or feet (hand-foot syndrome)
- increased level of potassium in the blood
- hair loss
- fluid buildup behind the retina in your eye

Tell your healthcare provider right away if you develop any nail or skin problems including nails separating from the nail bed, nail pain, nail bleeding, breaking of the nails, color or texture changes in your nails, infected skin around the nail, an itchy skin rash, dry skin, or cracks in the skin.

BALVERSA may affect fertility in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of BALVERSA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store BALVERSA?

- Store BALVERSA tablets at room temperature between 68°F to 77°F (20°C to 25°C).

Keep BALVERSA and all medicines out of the reach of children.

General information about the safe and effective use of BALVERSA.

Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use BALVERSA for a condition for which it was not prescribed. Do not give BALVERSA to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about BALVERSA that is written for healthcare professionals.

What are the ingredients in BALVERSA?

Active ingredient: erdafitinib

Inactive ingredients:

Tablet Core: Croscarmellose sodium, Magnesium stearate (from vegetable source), Mannitol, Meglumine, and Microcrystalline Cellulose.

Film Coating (Opadry amb II): Glycerol monocaprylocaprate Type I, Polyvinyl alcohol-partially hydrolyzed, Sodium lauryl sulfate, Talc, Titanium dioxide, Iron oxide yellow, Iron oxide red (for the orange and brown tablets only), Ferrosoferric oxide/iron oxide black (for the brown tablets only).

Manufactured for: Janssen Products, LP, Horsham, PA 19044, USA

For patent information: www.janssenpatents.com

© 2019 Janssen Pharmaceutical Companies

For more information call Janssen Products, LP at 1-800-526-7736 (1-800-JANSSEN) or go to www.BALVERSA.com.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: 10/2024